<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05080192</url>
  </required_header>
  <id_info>
    <org_study_id>844349</org_study_id>
    <nct_id>NCT05080192</nct_id>
  </id_info>
  <brief_title>Cardiovascular, Pulmonary, and Integrative Functional Phenotypes in COVID-19 Survivors - Effect of Fenofibrate</brief_title>
  <official_title>Cardiovascular, Pulmonary, and Integrative Functional Phenotypes in COVID-19 - Effect of Fenofibrate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The International multicenter FEnofibRate as a Metabolic INtervention for COVID-19 (FERMIN)&#xD;
      trial is being executed. The trial is testing a short intervention (10 days of fenofibrate&#xD;
      therapy) on 30-day outcomes in COVID-19. The overarching goal of this sub-study is to explore&#xD;
      the impact of fenofibrate on key longer term phenotypes of vascular, cardiac and pulmonary&#xD;
      health, integrated cardiopulmonary function, persistent/chronic symptoms and quality of life.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The International multicenter FEnofibRate as a Metabolic INtervention for COVID-19 (FERMIN)&#xD;
      trial is being executed. The aim of this trial is to assess the impact of fenofibrate&#xD;
      (administered for 10 days) to improve clinical outcomes in patients with COVID-19, assessed&#xD;
      at 30 days. However, given the accumulating evidence of chronic / long term sequelae of&#xD;
      COVID-19, it is important to assess the long-term impact of this intervention in this patient&#xD;
      population. The overarching goal of this substudy is to assess the impact of fenofibrate on&#xD;
      key intermediate phenotypes of vascular, cardiac and pulmonary health. We also aim to address&#xD;
      the impact of fenofibrate therapy (administered during the acute COVID-19 episode as part of&#xD;
      the parent FERMIN trial) on long-term integrated cardiopulmonary function, persistent/chronic&#xD;
      symptoms and quality of life. We will accomplish this via enrollment of previous FERMIN&#xD;
      participants from the University of Pennsylvania, in an phenotyping study designed to assess&#xD;
      vascular, cardiac and pulmonary status several months after the index episode of COVID-19. We&#xD;
      will perform these assessments ~6 months after initial randomization, among 40 FERMIN trial&#xD;
      participants enrolled at the University of Pennsylvania.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 26, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 28, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Flow Mediated dilation of the brachial artery</measure>
    <time_frame>~6 months</time_frame>
    <description>Flow Mediated dilation of the brachial artery measured with ultrasound. This is a metric of endothelial function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Arterial wave reflection magnitude</measure>
    <time_frame>~6 months</time_frame>
    <description>Arterial wave reflection magnitude measured with high fidelity arterial tonometry and wave separation analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Large Artery Stiffness</measure>
    <time_frame>~6 months</time_frame>
    <description>Carotid-femoral pulse wave velocity measured with arterial tonometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Myocardial function</measure>
    <time_frame>~6 months</time_frame>
    <description>Peak longitudinal strain assessed with echocardiography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diffusion capacity of lungs for carbon monoxide (DLCO)</measure>
    <time_frame>~6 months</time_frame>
    <description>Diffusion capacity of lungs for carbon monoxide (DLCO) measured during pulmonary function testing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aerobic capacity</measure>
    <time_frame>~6 months</time_frame>
    <description>Measured as Peak oxygen consumption during a cardiopulmonary exercise test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life</measure>
    <time_frame>~6 months</time_frame>
    <description>Quality of life measured with the Kansas City Cardiomyopathy questionnaire</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Fenofibrate recipients</arm_group_label>
    <description>Approximately 20 subjects who were randomized to the Fenofibrate arm in the FERMIN trial. This drug was administered for 10 days post-randomization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo recipients</arm_group_label>
    <description>Approximately 20 subjects who were randomized to the placebo arm in the FERMIN trial. This drug was administered for 10 days post-randomization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fenofibrate</intervention_name>
    <description>145 mg/d of Tricor (administered as part of the parent FERMIN trial) for 10 days, or renal corrected dose equivalent (depending on renal function)</description>
    <arm_group_label>Fenofibrate recipients</arm_group_label>
    <other_name>Tricor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo (once/day) for 10 days</description>
    <arm_group_label>Placebo recipients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma, urine, breath condensate, buffy coat, endothelial cells and RNA will be collected&#xD;
      from study subjects&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients will be screened from our FERMIN trial population. Participants will be approached&#xD;
        by a member of the study team for participation. Participants will undergo a comprehensive&#xD;
        assessment of key phenotypes (6±3 months after the index COVID-19 episode).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        • Having been eligible, enrolled and randomized in the parent FERMIN trial, completing all&#xD;
        study procedures up to the 30-day time point (as specified in the parent protocol).&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Prisoners/incarcerated individuals;&#xD;
&#xD;
          -  Pregnancy (potentially eligible patients of reproductive age will undergo a pregnancy&#xD;
             test). This exclusion is due to the fact that pregnancy may confound the various&#xD;
             cardiopulmonary phenotypes assessed in this study&#xD;
&#xD;
          -  Inability to provide informed consent.&#xD;
&#xD;
          -  History of cardiovascular disease (defined as heart failure, myocardial infarction,&#xD;
             coronary revascularization, serious arrhythmia, stroke, or peripheral artery disease),&#xD;
             glomerular disease or polycystic kidney disease prior to the index COVID-19 episode.&#xD;
&#xD;
          -  Estimated glomerular filtration rate &lt;30 mL/min/1.73m2 prior to the index COVID-19&#xD;
             episode.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Julio A Chirinos, MD, PhD</last_name>
    <phone>215-200-7779</phone>
    <email>julio.chirinos@pennmedicine.upenn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Katherine Greene, MPH</last_name>
    <phone>215-662-7580</phone>
    <email>katherine.greene@pennmedicine.upenn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julio A Chirinos, MD, PhD</last_name>
      <phone>215-200-7779</phone>
      <email>julio.chirinos@pennmedicine.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Katherine J Greene, MPH</last_name>
      <phone>215-662-7580</phone>
      <email>katherine.greene@pennmedicine.upenn.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Julio A Chirinos, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jordana B Cohen, MD, MSCE</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benjamin A Abramoff, MD, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert M Kotloff, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nadine Al-Naamani, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Franklin Caldera, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew C Hyman, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rajat Deo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nathaniel C Reisinger, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Kahn, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 17, 2021</study_first_submitted>
  <study_first_submitted_qc>October 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2021</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fenofibrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

